^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rina-S (rinatabart sesutecan)

    i
    Other names: PRO1184, GEN1184, GEN-1184
    Company:
    Genmab
    Drug class:
    Topoisomerase I inhibitor, Folate receptor 1-targeted antibody-drug conjugate
    Related drugs:
    1d
    RAINFOL-05: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Genmab
    New P2 trial
    |
    Rina-S (rinatabart sesutecan)
    9d
    RAINFOL-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer (clinicaltrials.gov)
    P3, N=544, Recruiting, Genmab | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    13d
    RAINFOL-01: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (clinicaltrials.gov)
    P1/2, N=764, Recruiting, Genmab | N=569 --> 764
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)
    1m
    RAINFOL-04: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy (clinicaltrials.gov)
    P3, N=528, Not yet recruiting, Genmab
    New P3 trial • Platinum sensitive
    |
    Avastin (bevacizumab) • Rina-S (rinatabart sesutecan)
    2ms
    RAINFOL-02: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Recruiting, Genmab | Trial primary completion date: May 2027 --> Feb 2027
    Trial primary completion date • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    3ms
    RAINFOL-03: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer (clinicaltrials.gov)
    P3, N=544, Not yet recruiting, Genmab
    New P3 trial
    |
    paclitaxel • doxorubicin hydrochloride • Rina-S (rinatabart sesutecan)
    8ms
    ENCORE: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (clinicaltrials.gov)
    P1/2, N=529, Recruiting, Genmab | N=404 --> 529 | Trial completion date: Oct 2026 --> Sep 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)
    11ms
    Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Recruiting, Genmab | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    11ms
    Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Not yet recruiting, Genmab | Trial completion date: Nov 2029 --> Apr 2028 | Trial primary completion date: Feb 2027 --> May 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    11ms
    Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (clinicaltrials.gov)
    P1/2, N=404, Recruiting, Genmab | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)
    1year
    Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Not yet recruiting, Genmab
    New P3 trial
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    over1year
    PRO1184-001: PRO1184 for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=374, Recruiting, ProfoundBio US Co. | N=134 --> 374 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jan 2025 --> Oct 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)